CYTARABINE

First approved in 1969

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H13N3O5
Molecular Weight	243.2166
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

InChIKey=UHDGCWIWMRVCDJ-CCXZUQQUSA-N

InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C9H13N3O5
Molecular Weight	243.2166
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Curator's Comment: Description was created using several sources including: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680 http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330

Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA polymerase lambda 4 Target ID: CHEMBL5367 Sources: http://www.drugbank.ca/drugs/DB00987	Inhibitor 8228

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic myelogenous leukemia 22 Sources: https://clinicaltrials.gov/ct2/show/NCT00333840	Primary		Phase III 663	Unknown Approved Use Unknown
Lymphomatous meningitis 3 Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf	Primary		Approved 8360	CYTARABINE Approved Use Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia. Launch Date -1.71072E10

C_max

Value	Dose	Co-administered	Analyte	Population
62.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf	100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN	DAUNORUBICIN	CYTARABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1900 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf	100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN	DAUNORUBICIN	CYTARABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
40.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf	100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN	DAUNORUBICIN	CYTARABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
80 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/12162758	50 mg single, intrathecal dose: 50 mg route of administration: Intrathecal experiment type: SINGLE co-administered:		CYTARABINE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366	Disc. AE: Cerebellar disorder NOS, Diarrhea... AEs leading to discontinuation/dose reduction: Cerebellar disorder NOS (grade 4, 66.7%) Diarrhea (grade 3, 66.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578	Disc. AE: Cerebellar disorder NOS, Cerebellar disorder NOS... AEs leading to discontinuation/dose reduction: Cerebellar disorder NOS (grade 4, 33.3%) Cerebellar disorder NOS (grade 5, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578
3 g/m2 2 times / day multiple, intravenous MTD Dose: 3 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 3 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.366	unhealthy, 16-76 n = 27 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 27 Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.366	Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.366
100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	Disc. AE: Bone marrow depression, Leukopenia... AEs leading to discontinuation/dose reduction: Bone marrow depression Leukopenia Thrombocytopenia Anemia Nausea Vomiting Diarrhea Abdominal pain Oral ulceration Hepatic dysfunction NOS Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Diarrhea	grade 3, 66.7% Disc. AE	4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366
Cerebellar disorder NOS	grade 4, 66.7% Disc. AE	4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366
Cerebellar disorder NOS	grade 4, 33.3% Disc. AE	4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578
Cerebellar disorder NOS	grade 5, 16.7% Disc. AE	4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578
Abdominal pain	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Anemia	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Bone marrow depression	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Diarrhea	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Hepatic dysfunction NOS	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Leukopenia	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Nausea	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Oral ulceration	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Thrombocytopenia	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Vomiting	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/15204103/ Page: 4.0	yes [IC50 6.6 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1709	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/15204103/ Page: 4.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28680	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28680
MolPort	MolPort-001-792-509	https://www.molport.com/shop/molecule-link/MolPort-001-792-509
Selleck Chemicals	Cytarabine(Cytosar-U)	http://www.selleckchem.com/products/Cytarabine(Cytosar-U).html
ZINC	ZINC000003795098	http://zinc15.docking.org/substances/ZINC000003795098
eMolecules	1012736	https://www.emolecules.com/cgi-bin/more?vid=1012736

PubMed

Title	Date	PubMed
Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis.	2001 Apr	11279646
Primary high-grade mucosa-associated lymphoid tissue-type lymphoma of the cervix presenting as a common endocervical polyp.	2001 Apr	11260632
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.	2001 Apr	11259616
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.	2001 Apr	11248327
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.	2001 Apr	11241350
The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway.	2001 Apr 1	11284018
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.	2001 Apr 1	11283125
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.	2001 Apr 1	11264164
Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents.	2001 Apr 1	11262191
The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.	2001 Apr 15	11290606
Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells.	2001 Apr 15	11286995
Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia.	2001 Apr-May	11293291
Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.	2001 Apr-May	11293286
[Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy 7 successfully treated with intermediate- and high-dose ara-C].	2001 Feb	11280917
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.	2001 Feb	11253603
Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.	2001 Feb	11232951
Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.	2001 Feb	11216707
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.	2001 Feb	11216706
Bilateral breast relapse in acute myelogenous leukemia.	2001 Feb	11216705
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.	2001 Feb	11211616
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].	2001 Feb	11181327
Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia.	2001 Feb	11167822
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.	2001 Feb 15	11233917
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.	2001 Feb 15	11181656
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.	2001 Feb 16	11273227
[Palpable mantel cell lymphoma in the breast].	2001 Feb 3	11229304
Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation.	2001 Jan	11281384
The biology and treatment of chronic myelogenous leukemia.	2001 Jan	11271979
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.	2001 Jan	11243404
[Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases].	2001 Jan	11235129
Aseptic meningitis in a child after systemic treatment with high dose cytarabine.	2001 Jan	11176579
Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.	2001 Jan 1	11196157
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.	2001 Jan 1	11196156
The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study.	2001 Jan-Feb	11277347
Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia--preliminary report.	2001 Jan-Feb	11208507
Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.	2001 Jan-Feb	11207969
Therapy of acute myeloid leukemia.	2001 Jan-Feb	11176038
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.	2001 Mar	11298592
Neutrophilic eccrine hidradenitis in two neutropaenic patients.	2001 Mar	11298106
[All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].	2001 Mar	11265415
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.	2001 Mar	11241435
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.	2001 Mar	11237060
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.	2001 Mar	11237056
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.	2001 Mar	11237055
Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.	2001 Mar	11226516
Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?	2001 Mar	11170283
Severe hepatic injury associated with lipid formulations of amphotericin B.	2001 Mar 1	11229863
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.	2001 Mar 15	11250987
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?	2001 Mar 15	11240249
Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.	2001 Mar 2	11237390

Patents

Sample Use Guides

In Vivo Use Guide

Induction therapy: DepoCyt (cytarabine liposome injection), 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3). Consolidation therapy: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).

Route of Administration: Intratracheal

In Vitro Use Guide

Human umbilical vein endothelial cells (HUVECs) and human osteosarcoma cell line (Cal72) were incubated with various concentrations of Cytarabine (Ara-C) (0.01–20 μM) for 3 days

Substance Class	Chemical Created by `admin` on `Thu Jul 06 22:08:08 UTC 2023` Edited by `admin` on `Thu Jul 06 22:08:08 UTC 2023`
Record UNII	04079A1RDZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CYTARABINE

Official Name

English

CYTARABINE [USP-RS]

Common Name

English

CYTARABINE [HSDB]

Common Name

English

CYTOSAR-U

Brand Name

English

CYTARABINE [EP MONOGRAPH]

Common Name

English

CYTARABINE [WHO-IP]

Common Name

English

CYTARABINUM [WHO-IP LATIN]

Common Name

English

DEPOCYT

Brand Name

English

ARACYTIN

Common Name

English

U-19,920

Code

English

CYTARABINE [USAN]

Common Name

English

CYTARABINE LIPOSOME

Common Name

English

CYTARABINE [VANDF]

Common Name

English

ARACYTIDINE

Common Name

English

SPONGOCYTIDINE

Common Name

English

CYTARABINE [MI]

Common Name

English

ARABINOCYTOSINE

Common Name

English

CYTARABINE [ORANGE BOOK]

Common Name

English

ARA-C

Common Name

English

CYTARABINE LIPOSOME [VANDF]

Common Name

English

CYTARABINE [USP IMPURITY]

Common Name

English

1-.BETA.-D-ARABINOFURANOSYLCYTOSINE

Common Name

English

Cytarabine [WHO-DD]

Common Name

English

VYXEOS COMPONENT CYTARABINE

Brand Name

English

NSC-287459

Code

English

U 19920A

Common Name

English

CYTARABINE [MART.]

Common Name

English

CYTARABINOSIDE

Common Name

English

CYTARABINE [JAN]

Common Name

English

U-19920

Code

English

ARACYTINE

Common Name

English

cytarabine [INN]

Common Name

English

CYTARABINE [EMA EPAR]

Common Name

English

2(1H)-PYRIMIDINONE, 4-AMINO-1-.BETA.-D-ARABINOFURANOSYL-

Common Name

English

CYTARABINE [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-ATC

L01XY01